Co-Diagnostics, Inc.
CODX Healthcare Medical Devices
Co-Diagnostics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $622,500.00, down 84.1% from fiscal 2024. In the quarter to June 2026, revenue grew 1.96%, EPS grew 78.9% and free cash flow grew 17.5%, each against the same quarter a year earlier.
Follow CODX
Co-Diagnostics, Inc. (CODX) EV/Sales
As of 16 October 2026, Co-Diagnostics, Inc. (CODX) trades at a EV/Sales of −1.2×. Over the past ten years it has ranged from −15.5× (March 2026) to 3,588× (June 2018); the current reading is higher than 27% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −8.3× | — |
| FY2024 | −1.8× | — |
| FY2023 | −2.5× | — |
| FY2022 | 0.0× | — |
| FY2021 | 1.7× | (36.43%) |
| FY2020 | 2.7× | (95.89%) |
| FY2019 | 65.5× | (85.17%) |
| FY2018 | 442× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 13.5× | — |
| Mar 2026 | −5.6× | — |
| Dec 2025 | −8.3× | — |
| Sep 2025 | 3.1× | — |
| 33 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NVNO enVVeno Medical Corporation compare | −63.5× |
| CODX Co-Diagnostics, Inc. | −1.2× |
| AMIX Autonomix Medical, Inc. compare | n/m |
| WOK WORK Medical Technology Group LTD compare | n/m |
| TBIO Telesis Bio Inc. compare | 0.1× |
| INBS Intelligent Bio Solutions Inc. compare | 0.2× |
| VVOS Vivos Therapeutics, Inc. compare | 0.4× |
| TRIB Trinity Biotech PLC compare | 3.0× |
| VNRX VolitionRX Limited compare | 4.0× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)